kabutan

STELLA PHARMA CORPORATION(4888) Summary

4888
TSE Growth
STELLA PHARMA CORPORATION
248
JPY
-4
(-1.59%)
Dec 5, 11:30 am JST
1.59
USD
Dec 4, 9:30 pm EST
Result
PTS
outside of trading hours
247.7
Dec 5, 11:27 am JST
Summary Chart Historical News Financial Result
PER
PBR
2.91
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
248 JPY 1.59 USD
Previous Close Dec 4
252 JPY 1.62 USD
High Dec 5, 9:45 am
252 JPY 1.62 USD
Low Dec 5, 9:04 am
247 JPY 1.59 USD
Volume
49,900
Trading Value
0.01B JPY 0.08M USD
VWAP
248.82 JPY 1.61 USD
Minimum Trading Value
24,800 JPY 159 USD
Market Cap
8.44B JPY 0.05B USD
Number of Trades
84
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
422
1-Year High Jul 28, 2025
3,059
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 1,760,400
Nov 21, 2025 0 1,799,900
Nov 14, 2025 0 1,832,300
Nov 7, 2025 0 1,781,200
Oct 31, 2025 0 1,742,900
Company Profile
STELLA PHARMA CORPORATION is a subsidiary of Stella Chemifa. The company develops, manufactures, and sells boron-based pharmaceuticals for cancer radiotherapy.
Sector
Pharmaceuticals
STELLA PHARMA CORPORATION is a biotech venture company within the Stella Chemifa group. It specializes in the development, manufacturing, and sales of "Steboronine," a boron-based pharmaceutical for cancer radiotherapy. The company has obtained the world's first approval for a drug used in Boron Neutron Capture Therapy (BNCT). Steboronine has been launched in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. Clinical trials are currently underway to expand its applications to recurrent malignant glioma and recurrent high-grade meningioma. Leveraging its strength in high-purity boron-10 enrichment technology, STELLA PHARMA CORPORATION aims to expand its business both domestically and internationally.